Abstract
Thyroid stimulating hormone receptor messenger RNA (TSHR-mRNA) is over-expressed in thyroid cancer patients, which indicates that TSHR-mRNA is a potential biomarker of thyroid cancer. However, system evaluation for TSHR-mRNA as a diagnostic biomarker of thyroid cancer is deficient. The performance of TSHR-mRNA for thyroid cancer diagnosis was evaluated in this study. Three common international databases as well as a Chinese database were applied for literature researching. Quality assessment of the included literatures was conducted by the QUADAS-2 tool. Totally, 1027 patients from nine studies eligible for the meta-analysis were included in this study. Global sensitivity and specificity for the positivity of TSHR-mRNA in the thyroid cancer diagnosis is 72% and 82%. The value of AUC for this test performance was 0.84. Our meta-analysis suggests that TSHR-mRNA might be a potential biomarker to complete present diagnostic methods for early and precision diagnosis of thyroid cancer. Notably, this findings need validation thorough large-scale clinical studies.
Highlights
Thyroid cancer is one of the most common cancers in the endocrine system, and the incidence of thyroid cancer is about 1%, and it is the main cause of death in the endocrine system [1]
Titles and abstracts were preliminarily reviewed and a www.impactjournals.com/oncotarget total of 55 articles were excluded for various reasons
The preoperative evaluation of thyroid nodules currently depends on fine needle aspiration (FNA) biopsy
Summary
Thyroid cancer is one of the most common cancers in the endocrine system, and the incidence of thyroid cancer is about 1%, and it is the main cause of death in the endocrine system [1]. There are around 44670 new cases and 1690 deaths of thyroid cancer every year [2]. The average annual percentage for thyroid cancer increased 5.3% per year [3]. The diagnostic methods of thyroid cancer mainly include ultrasound, CT and fine-needle aspiration cytology. It can improve the accuracy of diagnosis of thyroid cancer. There are ThyroSeqV2 generation sequencing assay to improve the diagnosis of benign and malignant thyroid cancer method [5], which is high accuracy but high cost, and can not be popularized. New methods is necessary in the diagnosis of thyroid cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
